Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

20055,340 citationsJournal Articlebronze Open Access

Authors

Edward H. Romond · NSABP Foundation

Edith A. Perez · Jacksonville College

John Bryant · NSABP Foundation

Vera J. Suman · Mayo Clinic in Arizona

Charles E. Geyer

Nancy E. Davidson · Sidney Kimmel Comprehensive Cancer Center

Elizabeth Tan-Chiu · NSABP Foundation

Abstract

Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)

Topics & Keywords

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 353, Issue 16, pp. 1673-1684

DOI: 10.1056/nejmoa052122

Field-Weighted Citation Impact: 153.97